Beyond Teplizumab: New Strategies Emerge to Prevent Type 1 Diabetes

Type 1 diabetes mellitus remains a serious and growing global health challenge. Despite advances in insulin therapy and glucose monitoring, the disease's underlying autoimmune destruction of pancreatic beta-cells continues unchecked in most patients. Prevention — either stopping or substantially delaying onset — has become a major research priority, particularly for high-risk individuals identified through genetic screening or autoantibody positivity.

This comprehensive 2025 review from researchers at the University of Queensland surveys the landscape of T1DM prevention therapeutics. Central to the discussion is teplizumab, the first and currently only FDA-approved therapy shown to delay T1DM onset. As an Fc-receptor non-binding anti-CD3 monoclonal antibody, it modulates T-cell activity to slow autoimmune beta-cell destruction. However, its intravenous delivery, risk of generalized immunosuppression, and adverse effect profile present real barriers to widespread clinical adoption.

A key conceptual shift highlighted by the authors is the recognition that beta-cells are active agents in their own destruction — not merely innocent bystanders. Their heterogeneity, vulnerability to cellular stressors, and capacity to present antigens to immune cells fundamentally changes what an effective prevention strategy must address. Therapies must protect beta-cell function and mass, not just suppress immune attack.

The review introduces RAGE (receptor for advanced glycation end products) as a compelling alternative or complementary target. RAGE engages diverse ligands including AGEs — a class of molecules formed under hyperglycemic conditions, with HbA1c being the most clinically recognized. By modulating RAGE signaling, it may be possible to interrupt early inflammatory and metabolic pathways that prime the autoimmune response.

While the review is forward-looking and hopeful, it is constrained by the absence of large-scale clinical trial data for most emerging approaches. Teplizumab's approval, though imperfect, signals that prevention is achievable — and may catalyze development of safer, more accessible next-generation therapies.